Corundum Systems Biology Invests in a Biotech Company Specializing in Improved Reproductive Health for Women

Investment to Support Freya Biosciences Drive Development of Lead Drug Candidates to Positively AffectTreatment of Pregnancies

Tokyo December 21, 2023 — Corundum Systems Biology Inc., a Japanese company that brings together microbiome research and business creation, has newly invested in the field of women’s reproductive health.  Corundum’s latest investment is part of the Series A funding, led by Sofinnova Partners and OMX Ventures, that raised a total of USD38 million for Freya Biosciences.  Freya is a clinical-stage startup dedicated to advance women’s reproductive immunotherapies. Freya utilizes vaginal microbial immunotherapeutics for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART), including in vitro fertilization (IVF). .   

Corundum Systems Biology will also support the business development of Freya Biosciences in Japan and Korea, where demand for IVF is particularly high.

“As a company dedicated to women’s health, we are thrilled to have Corundum Systems Biology support our groundbreaking work to enable new therapeutic options in the area of fertility and beyond,” says Colleen Acosta, Freya Biosciences. “Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to their burden on human health.  Our initial focus on infertility affects millions of couples worldwide. Japan and Korea are no exceptions.”

“Freya’s approach to positively affect reproductive health conditions in women through microbial immunotherapies is a completely innovative way to address reproductive health issues for which treatments aren’t yet available,” says Hidehiko Otake, CEO of Corundum Systems Biology Inc.  “We are truly excited to support Freya’s quest to gain a more comprehensive understanding of women’s health and to develop solutions to introduce viable solutions to infertility.” 

Freya Biosciences is a clinical-stage biotech company with headquarters in Copenhagen, Denmark and Boston, Massachusetts dedicated to reimagining women’s health and redefine fertility for those previously deprived of options.  With a focus on microbial immunotherapies, Freya addresses immune drivers underlying a range of reproductive health conditions to create a future where everyone is empowered with optimal reproductive health:

Corundum Systems Biology, headquartered in Tokyo, has as its mission to become an Innovation Hub in the field of microbiome, a critical field with potential to unlock next-generation life science technologies and bettering human health and quality of life: